The laboratory-based research program of Gregory J. Gores, M.D., is focused on mechanisms of liver cell death, especially apoptosis. He employs disease-relevant models to unravel the fundamental cellular processes contributing to liver injury during cholestasis and fatty liver diseases. In addition, Dr. Gores' lab is also interested in the mechanisms by which cancer cells escape from cell death in order to undergo malignant transformation and metastases.
- Role of death receptors in hepatocyte apoptosis
- Carcinogenesis of biliary epithelia
Dr. Gores develops and participates in clinical research protocols for the treatment of hepatobiliary neoplasia. Current protocols relate to innovative multidisciplinary efforts in the diagnosis and treatment of hepatocellular carcinoma and cholangiocarcinoma. Dr. Gores and his team also participate in unique single-institution and multi-institution treatment protocols for these diseases.
- Hepatobiliary neoplasia
- Hepatocellular cancer
Significance to patient care
Inhibition of apoptosis is a viable therapeutic strategy for minimizing liver injury during cholestasis, viral, autoimmune and fatty liver diseases. Selective induction of apoptosis in transformed cells is also a goal for treating advanced hepatobiliary malignancies. Fundamental mechanistic insights into the mechanisms of liver cell apoptosis may help to provide rational pharmacologic approaches for the treatment of inflammatory and malignant hepatobiliary diseases.
- Executive dean for research, Mayo Clinic, 2013-present
- Reuben R. Eisenberg Endowed Professor in Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, 2001-present
- Named, Best Doctors in America, 2005-2013
- Recipient, Research Career Achievement Award, Mayo Clinic Department of Internal Medicine, 2010
- Recipient, Distinguished Investigator Award, Mayo Clinic, 2008
- Recipient, Outstanding Mentorship Award, Mayo Clinic Department of Internal Medicine, 2004